甲氨蝶呤在维持溃疡性结肠炎无激素缓解或应答方面不优于安慰剂
这项48周随机安慰剂对照试验纳入179例活动性溃疡性结肠炎患者,先接受16周开放标签甲氨蝶呤诱导治疗,第16周无激素应答者随机继续甲氨蝶呤25 mg/周(n=44)或安慰剂(n=40)维持32周。维持期安慰剂组60%(24/40)与甲氨蝶呤组66%(29/44)复发(P=.75),第48周无激素临床缓解率分别为30%(12/40)与27%(12/44)(P=.86),甲氨蝶呤未优于安慰剂。
要点
- 活动性溃疡性结肠炎患者经甲氨蝶呤诱导后,维持期甲氨蝶呤25 mg/周不优于安慰剂。
- 维持期复发率:安慰剂组60%(24/40)vs 甲氨蝶呤组66%(29/44),P=.75。
- 第48周无激素临床缓解率:安慰剂组30%(12/40)vs 甲氨蝶呤组27%(12/44),P=.86。
核心结论
- 在诱导治疗期间获得无激素应答的溃疡性结肠炎患者中,皮下甲氨蝶呤25 mg/周在预防复发方面不优于安慰剂。
研究设计与样本
- 48周随机、安慰剂对照试验,2012年2月至2016年5月纳入179例活动性溃疡性结肠炎患者(Mayo评分6-12分且内镜亚评分≥2分),此前接受过常规或生物制剂治疗。
- 研究包括16周开放标签甲氨蝶呤诱导期,随后32周双盲、安慰剂对照维持期;患者接受皮下甲氨蝶呤25 mg/周及12周激素逐渐减量。
- 第16周无激素应答者随机继续甲氨蝶呤25 mg/周(n=44)或安慰剂(n=40)至第48周。
主要发现
- 91例患者(51%)在第16周达到应答,84例进入维持期研究。
- 维持期安慰剂组60%(24/40)与甲氨蝶呤组66%(29/44)出现溃疡性结肠炎复发(P=.75)。
- 第48周安慰剂组30%(12/40)与甲氨蝶呤组27%(12/44)达到无激素临床缓解且无需额外治疗(P=.86)。
- 未检测到甲氨蝶呤新的安全性信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Parenteral methotrexate induces clinical remission but not endoscopic improvement of mucosal inflammation in patients with ulcerative colitis (UC). We performed a randomized, placebo-controlled trial to assess the efficacy of parenteral methotrexate in maintaining steroid-free response or remission in patients with UC after induction therapy with methotrexate and steroids. METHODS: We performed a 48-week trial, from February 2012 through May 2016, of 179 patients with active UC (Mayo score of 6-12 with endoscopy subscore ≥ 2) despite previous conventional or biological therapy. The study comprised a 16-week open label methotrexate induction period followed by a 32-week double-blind, placebo-controlled maintenance period. Patients were given subcutaneous methotrexate (25 mg/wk) and a 12-week steroid taper. At week 16, steroid-free responders were randomly assigned to groups that either continued methotrexate (25 mg/wk, n = 44) or were given placebo (n = 40) until week 48. We compared the efficacy of treatment by analyzing the proportion of patients who remained relapse free and were in remission at week 48 without use of steroids or other medications to control disease activity. RESULTS: Ninety-one patients (51%) achieved response at week 16, and 84 patients were included in the maintenance period study. During this period, 60% of patients in the placebo group (24/40) and 66% in the methotrexate group (29/44) had a relapse of UC (P = .75). At week 48, 30% of patients in the placebo group (12/40) and 27% of patients in the methotrexate group (12/44) were in steroid-free clinical remission without need for additional therapies (P = .86). No new safety signals for methotrexate were detected. CONCLUSIONS: Parenteral methotrexate (25 mg/wk) was not superior to placebo in preventing relapses of UC in patients who achieved steroid-free response during induction therapy. ClinicalTrials.gov, Number: NCT01393405.
引用
- Herfarth H, Barnes EL, Valentine JF, et al. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology. 2018. PMID: 29964043. doi:10.1053/j.gastro.2018.06.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。